{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-042203","form_type":"8-K","ticker":"RBOT","cik":"0001812173","company_name":"Vicarious Surgical Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.824774+00:00","generated_at":"2026-05-21T17:23:31.947892+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vicarious Surgical Q1 2025: GAAP net loss $15.4M; FY cash burn guided ~$50M","bullets":["GAAP net loss $15.4M ($2.60/shr) vs $17.0M ($2.90) Q1 2024; adjusted net loss $15.3M ($2.58/shr).","Operating expenses $15.7M, down 2% YoY; R&D $9.4M, G&A $5.3M, S&M $1.0M.","Cash and investments $37.4M at March 31, 2025; Q1 cash burn $11.7M.","Full-year 2025 cash burn guidance approximately $50 million.","CEO says company is 'just a few quarters away' from first clinical patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-042203","json":"https://secwatch.observer/filing/0001213900-25-042203.json","markdown":"https://secwatch.observer/filing/0001213900-25-042203.md","text":"https://secwatch.observer/filing/0001213900-25-042203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025042203/0001213900-25-042203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812173/000121390025042203/ea0241839-8k_vicarious.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T17:23:31.947892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}